Invex Therapeutics Ltd (ASX:IXC)
Australia · Delayed Price · Currency is AUD 0.1300
+0.0100 (8.33%)
Aug 26, 2026, 10:50 AM AEST
Invex Therapeutics Market Cap
Invex Therapeutics has a market cap or net worth of 9.02 million as of August 26, 2026. Its market cap has increased by 20.00% in one year.
Market Cap
9.02M
Enterprise Value
4.42M
Revenue
229.08K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.13
ChartMarket Cap Chart
Since July 5, 2019, Invex Therapeutics's market cap has decreased from 59.13M to 9.02M, a decrease of -84.75%. That is a compound annual growth rate of -23.17%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 21, 2026 | 9.02M | - |
| Dec 30, 2025 | 9.02M | 81.82% |
| Dec 23, 2024 | 4.96M | -18.52% |
| Dec 27, 2023 | 6.09M | -85.14% |
| Dec 28, 2022 | 40.96M | -22.70% |
| Dec 31, 2021 | 52.98M | -1.40% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Jul 5, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Ceryvyn Therapeutics | 15.05M |
| ReNerve | 13.27M |
| Cambium Bio | 12.36M |
| Immuron | 12.09M |
| AdAlta | 11.24M |
| Vectus Biosystems | 9.22M |
| Bio-Gene Technology | 8.32M |
| Zelira Therapeutics | 5.95M |